The purpose of this chapter is to provide a brief review of the literature on botulinum
neurotoxin and tetanus toxin. This review will emphasize studies that pertain to cellular and …

Botulinum (BoNT, serotypes AG, see also Chapter 2) and tetanus (TeNT) neurotoxins are
known under the generic term of clostridial neurotoxins. These dichainal proteins comprise a …

The type A neurotoxin produced by Clostridium botulinum is a potent neuromuscular
blocking agent which causes paralysis by preventing the release of neurotransmitter from …

Botulinum neurotoxins (BoNTs) have been used as therapeutic agents in the clinical
treatment of a wide array of neuromuscular and autonomic neuronal transmission disorders …

For more than three decades, Botulinum neurotoxin (BoNT) has been used to treat a variety
of clinical conditions such as spastic or dystonic disorders by inducing a temporary paralysis …

Botulinum neurotoxin (BoNT) binds to and internalizes its light chain into presynaptic
compartments with exquisite specificity. While the native toxin is extremely lethal …

Botulinum neurotoxins (BoNTs) inhibit neurotransmitter release by hydrolysing SNARE
proteins. The most important serotype BoNT/A employs the synaptic vesicle glycoprotein 2 …

Botulinum toxin serotype A has proven to be a successful and valuable therapeutic protein
when dosage, frequency of treatment and variety of treated clinical conditions are …

Botulinum neurotoxins are used clinically for conditions characterized by hyperexcitability of
peripheral nerve terminals and hypersecretory syndromes. These neurotoxins are …

Botulinum neurotoxins are the most potent acute lethal toxins known, and yet for the last two
decades they, and in particular serotype A, have found increasing use in the clinical …